"I will miss the study, god bless you all": Participation in a nutritional chemoprevention trial

Ethnicity and Disease

Volumn 14, Issue 4, 2004, Pages 469-475

  Moreno Black, Geraldine ^a   Shor Posner, Gail ^b   Miguez, Maria Jose ^b   Burbano, Ximena ^c   O'Mellan, Sandra ^b   Yovanoff, P ^a  

^a UNIVERSITY OF OREGON   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Barriers to participation; Participant interpretation; Randomized control clinical trials; Retention

Indexed keywords

PLACEBO; SELENIUM;

ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; AWARENESS; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG ABUSE; FEMALE; HEALTH STATUS; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; METHODOLOGY; MINORITY GROUP; MOTIVATION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SELECTION; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SELF CONCEPT; SELF ESTEEM; SOCIAL BEHAVIOR; STANDARD; WELLBEING;

ADULT; ATTITUDE TO HEALTH; DIETARY SUPPLEMENTS; FEMALE; FLORIDA; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RESEARCH SUBJECTS; SELENIUM; SOCIAL SUPPORT;

EID: 7444225275     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Moorman P, Newman B, Millikan R, Tse C, Sandler D. Participation rates in a case-controlled study: the impact of age, race, and race of interviewer. Ann Epidemiol. 1999;9:188-195.
2. Senturia Y, Mortimer MK, Baker D, et al. Successfid techniques for retention of study participants in an inner-city population. Control Clin Trials. 1998;19:544-554.
3. Hill P, Humenick S. Comparison of subjects who fidly versus minimally participated in a breast-feeding study. West J Nurs Res. 1995; 17:328-334.
4. Moser D, Dracup K, Doering L. Factors differentiating dropouts from completers in a longitudinal, multicenter clinical trial. Nurs Res. 2000;49:9-16.
5. Verheggen F, Nieman F, Jonkers R. Determinants of patient participation in clinical trial studies requiring informed consent: why patients enter a clinical trial. Patient Educ Couns. 1998;35:111-125.
6. Morse EV, Simon PM, Besch CL, Walker J. Issues of recruitment, retention, and compliance in community based clinical trials with traditionally underserved populations. Appl Nurs Res. 1995;8:8-14.
7. Riesch S, Tosi C, Thurston C. Accessing young adolescents and their families for research. J Nurs Sch. 1999;31:323-326.
8. Stasiewicz P, Stalker R. A comparison of three interventions on pretreatment dropout rates in an outpatient substance abuse clinic. Addict Behav. 1999;24:579-582.
9. Good M, Schuler L. Subject retention in a controlled clinical trial. J Adv Nurs. 1997;26: 351-355.
10. Naranjo L, Dirksen S. The recruitment and participation of Hispanic women in research: a learning process. Public Health Nurs. 1998; 15:25-29.
11. Young C, Dombrowski M. Psychosocial influences in research subject recruitment, enrollment, and retention. Soc Work Health Care 1990;14:43-57.
12. Davis LL, Broome ME, Cox RP. Maximizing retention in community-based clinical trials. J Nurs Sch. 2002;34:47-53.
13. Cassileth BR, Lusk EJ, Miller DS, Hurwitz S. Attitudes toward clinical trials among patients and the public. JAMA. 1982;248:968-970.
14. Llewellyn-Thomas HA, McGreal MJ, Thiel EC, Fine S, Erlichman C. Patients' willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation. Soc Sci Med. 1991;32:35-42.
15. Selvin M, Mossman J, Bowling A, et al. Volunteers or victims: patients' views of randomized cancer clinical trials. Br J Cancer. 1995; 71:1270-1274.
16. Green B, Partridge EE, Mona M, et al. African-American attitudes regarding cancer clinical trials and research studies: results from focus group methodology. Ethn Dis. 2000;10: 76-86.
17. Charles C, Redko C, Whelan T, Gafni A, Reyno L. Doing nothing is no choice: lay constructions of treatment decision-making among women with early stage breast cancer. Soc Sci Med. 1978;20:71-95.
18. Daugherty C, Ratain MJ, Grochowski E, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995;13:1062-1072.
19. Mohanna K, Tuana K. Withholding consent to participate in clinical trials: decisions of pregnant women. Br J Obstet Gynaecol. 1999; 106:892-897.
20. Schwartz CE, Fox BH. Who says yes? Identifying selection biases in a psychosocial intervention study of multiple sclerosis. Soc Sci Med. 1995;40:359-370.
21. Appelbaum PS, Roth LH, Lidz CW, Benson P, Winslade W. False hopes and best data: consent to research and therapeutic misconception. Hastings Center Rep. April 1997:20-24.
22. Featherstone K, Donovan JL. "Why don't they just tell me straight, why allocate it?" The struggle to make sense of participating in a randomized controlled trial. Soc Sci Med. 2002; 55:709-719.
23. Snowdon C, Garcia J, Elbourne D. Making sense of randomization: response of parents of critically ill babies to random allocation of treatment in a clinical trial. Soc Sci Med. 1997;45:1337-1355.
24. Escobar I, Campo M, Martin J, et al. Factors affecting patient adherence to highly active antiretroviral therapy. Ann Pharmacother. 2003;37:775-781.
25. Moatti JP, Carrieri MP, Spire B, et al. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS. 2000;14: 151-155.
26. Baum M, Shor-Posner G, Lai S, et al. High risk of HIV-related mortality is associated with selenium deficiency. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:370-374.
27. Clark LC, Combs GS, Turnbull BW. The nutritional prevention of cancer with selenium 1983-1993: a randomized clinical trial. JAMA 1996;276:957-1963.
28. Kiremidjian-Schumacher L, Roy M, Wishe HI, Cohen MW, Stotzky G. Regulation of cellular immune responses by selenium. Biol Trace Elem Res. 1992;22:23-35.
29. Taylor EW, Nadimpalli RG, Ramananathan CS. Geneomic structure of viral agents in relation to the biosynthesis of selenoproteins. Biol Trace Elem Res. 1997;56:63-91.
30. Kleinman A. Patients and Healers in The Context of Culture Berkeley, Calif University of California Press; 1980:104-118.
31. Benisovich SV, King AC. Meaning and knowledge of health among older adult immigrants from Russia: a phenomenological study. Health Educ Res. 2003;18(2):135-144.
32. Henwood K, Pidgeon N. Grounded theory in psychological research. In: Camic PM, Rhodes JE, Yardley L, eds. Qualitative Research in Psychology. Washington, DC: American Psychological Association; 2002:131-156.
33. Marshall C, Rossman GB. Designing Qualitative Research. 3rd ed. Thousand Oaks, Calif Sage Publications; 1999.
34. Shor-Posner G, Miguez MJ, Pineda LM, et al. Impact of selenium status on the pathogenesis of mycobacterial disease in HIV-1 infected drug users during the era of highly active antiretroviral therapy. JAIDS. 2002; 29(2):169-173.
35. Burbano X, Miguez-Burbano MJ, McCollister K, et al. Impact of selenium chemoprevention clinical trial on hospital admissions of HIV infected participants. HIV Clin Trials J. 2002;3(6):483-491.
36. Shor-Posner G, Lecusay R, Miguez MJ, et al. Psychological burden in the era of HAART: impact of selenium therapy. Int J Psychiatry Med. 2000;33:55-69.
37. Shumaker SA, Dugan E, Bowen DJ. Enhancing adherence in randomized controlled clinical trials. Control Clin Trials. 2000;21:226S-232S.